CD8A and breast cancer: However, icaritin suppresses liver cancer by reducing hematopoietic stem cells and PMN-MDSCs in liver cancer (Hepa1-6) cells and exerts anti-cancer effects by reducing the proportion of MDSCs and restoring CD8+ T cell function in breast cancer (4T1) cells as well [706, 707].